Frédéric Martino
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Frédéric Martino has a total of 133 co-authors. Here are the top co-authors by number of shared publications:
- Marc Romana
Université Paris Cité et Université des Antilles INSERM BIGR F-75015 Paris France
3 shared publications Adrien Pons
Réanimation Médicale et Chirurgicale, CHU de la Guadeloupe, Guadeloupe, France
2 shared publications- Amélie Le Gouge
Inserm CIC 1415, Tours, France
2 shared publications - Anne Bretagnol
Service de Médecine Intensive Réanimation, Centre Hospitalier Régional d’Orléans, Orléans, France
2 shared publications - Benoit Tressieres
Caribbean Clinical Investigation Center, Inserm CIC 2504, University Hospital of Guadeloupe, Pointe-À-Pitre/Abymes, France
2 shared publications - Bertrand Guidet
Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, Equipe PEPITES, AP-HP, Hôpital Saint Antoine, Paris, France
2 shared publications
Latest Publications
- Open Access
- 14 October 2026
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 30 (20) , e71390
Activation of Platelet Caspase‐1 and P‐Selectin Over‐Expression in Sickle Cell Disease Patients: An Involvement of NLRP3 Inflammasome?
Sickle cell disease (SCD) is characterized by hemolytic anaemia, painful vaso‐occlusive crises, and chronic inflammation resulting partly from platelet activation. It has been shown that platelets express the nucleotide‐binding domain leucine‐rich repeat containing protein 3 (NLRP3) and the apoptosis‐associated speck‐like protein containing a CARD (ASC), forming the NLRP3 inflammasome, which controls activation of caspase‐1 and cleavage of interleukin‐1β (IL‐1β). Bruton tyrosine kinase (BTK), known to activate the NLRP3 inflammasome, is also expressed in platelets. In SCD, platelets are activated and can secrete increased quantities of IL‐1β, suggesting a possible activation of the NLRP3 inflammasome. Here, we assessed platelet P‐selectin expression, caspase‐1 activation, platelet–neutrophil aggregate formations by flow cytometry and BTK phosphorylation by Western blot in a cohort of 81 adult SCD patients at steady state condition (34 SC and 47 SS patients). We showed an increase in platelet activation in sickle patients and a high level of platelet–neutrophil aggregate in SS patients compared to healthy subjects (17 AA). We also demonstrated platelet caspase‐1 activation in SCD patients and obtained data suggesting for the first time NLRP3 inflammasome activation in SC patients. Further studies are needed to understand the mechanism of caspase‐1 activation and evaluate the potential therapeutic efficiency of Ibrutinib, a BTK inhibitor.
- 14 October 2026
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 30 (20) , e71390
Open AccessActivation of Platelet Caspase‐1 and P‐Selectin Over‐Expression in Sickle Cell Disease Patients: An Involvement of NLRP3 Inflammasome?
Sickle cell disease (SCD) is characterized by hemolytic anaemia, painful vaso‐occlusive crises, and chronic inflammation resulting partly from platelet activation. It has been shown that platelets express the nucleotide‐binding domain leucine‐rich repeat containing protein 3 (NLRP3) and the apoptosis‐associated speck‐like protein containing a CARD (ASC), forming the NLRP3 inflammasome, which controls activation of caspase‐1 and cleavage of interleukin‐1β (IL‐1β). Bruton tyrosine kinase (BTK), known to activate the NLRP3 inflammasome, is also expressed in platelets. In SCD, platelets are activated and can secrete increased quantities of IL‐1β, suggesting a possible activation of the NLRP3 inflammasome. Here, we assessed platelet P‐selectin expression, caspase‐1 activation, platelet–neutrophil aggregate formations by flow cytometry and BTK phosphorylation by Western blot in a cohort of 81 adult SCD patients at steady state condition (34 SC and 47 SS patients). We showed an increase in platelet activation in sickle patients and a high level of platelet–neutrophil aggregate in SS patients compared to healthy subjects (17 AA). We also demonstrated platelet caspase‐1 activation in SCD patients and obtained data suggesting for the first time NLRP3 inflammasome activation in SC patients. Further studies are needed to understand the mechanism of caspase‐1 activation and evaluate the potential therapeutic efficiency of Ibrutinib, a BTK inhibitor.
- Open Access
- 17 October 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (20) , 11140
Influence of Common Gene Variants on Lipid Levels and Risk of Coronary Heart Disease in Afro-Caribbeans
A lower mortality rate from coronary artery disease (CAD) and a more favourable lipid profile have been reported in Afro-Caribbeans compared with people of European ancestry. The aim of this study was to determine whether common lipid variants identified in other populations are associated with lipid levels and CAD in Afro-Caribbeans. We studied 705 Afro-Caribbeans (192 with CAD) who were genotyped for 13 lipid-associated variants. We calculated three polygenic risk scores (PRSs) for elevated LDL (LDL-PRS), decreased HDL (HDL-PRS), and elevated triglycerides (TG-PRS). LDL-PRS, HDL-PRS, and TG-PRS were associated with LDL, HDL, and TG levels, respectively. The LDL-PRS was positively associated with LDL > 2.6 mmol/L and with LDL > 3.0 mmol/L with ORs (odds ratios) of 1.33 (95% confidence interval (CI) = 1.14–1.56) and 1.40 (CI = 1.21–1.62), respectively. The HDL-PRS was associated with a low HDL category (HDL < 1.03 mmol/L) with an OR of 1.3 (CI = 1.04–1.63) and inversely associated with a high HDL category (HDL > 1.55 mmol/L) with an OR of 0.79 (CI = 0.65–0.96). The LDL-PRS was positively associated with CAD after adjustment for age, gender, hypertension, diabetes, and smoking with an OR of 1.27 (CI = 1.06–1.51) but not the HDL-PRS nor the TG-PRS. Results of the present study indicate that common lipid variants are associated with lipid levels and prevalent CAD in Afro-Caribbeans.
- 17 October 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (20) , 11140
Open AccessInfluence of Common Gene Variants on Lipid Levels and Risk of Coronary Heart Disease in Afro-Caribbeans
A lower mortality rate from coronary artery disease (CAD) and a more favourable lipid profile have been reported in Afro-Caribbeans compared with people of European ancestry. The aim of this study was to determine whether common lipid variants identified in other populations are associated with lipid levels and CAD in Afro-Caribbeans. We studied 705 Afro-Caribbeans (192 with CAD) who were genotyped for 13 lipid-associated variants. We calculated three polygenic risk scores (PRSs) for elevated LDL (LDL-PRS), decreased HDL (HDL-PRS), and elevated triglycerides (TG-PRS). LDL-PRS, HDL-PRS, and TG-PRS were associated with LDL, HDL, and TG levels, respectively. The LDL-PRS was positively associated with LDL > 2.6 mmol/L and with LDL > 3.0 mmol/L with ORs (odds ratios) of 1.33 (95% confidence interval (CI) = 1.14–1.56) and 1.40 (CI = 1.21–1.62), respectively. The HDL-PRS was associated with a low HDL category (HDL < 1.03 mmol/L) with an OR of 1.3 (CI = 1.04–1.63) and inversely associated with a high HDL category (HDL > 1.55 mmol/L) with an OR of 0.79 (CI = 0.65–0.96). The LDL-PRS was positively associated with CAD after adjustment for age, gender, hypertension, diabetes, and smoking with an OR of 1.27 (CI = 1.06–1.51) but not the HDL-PRS nor the TG-PRS. Results of the present study indicate that common lipid variants are associated with lipid levels and prevalent CAD in Afro-Caribbeans.
- Open Access
- 24 July 2024
- Published by Wolters Kluwer Health in Journal of Neurosurgical Anesthesiology
- Vol. 37 (3) , 279-287
Outcome of Aneurysmal Subarachnoid Hemorrhage Not Altered With Transatlantic Airplane Transfer: A Bicentric Matched Case-control Study
Objective: It is recommended that ruptured cerebral aneurysms are treated in a high-volume center within 72 hours of ictus. We assessed the impact of long-distance aeromedical evacuation in patients presenting aSAH. Methods: This case-control study compared patients with aneurysmal subarachnoid hemorrhage (aSAH) who had a 6750 km air transfer from Guadeloupe (a Caribbean island) to Paris, France, for neurointerventional management in a tertiary center with a matched cohort from Paris region treated in the same center over a 10-year period (2010 to 2019). The 2 populations were matched on age, sex, World Federation of Neurological Surgeons score, and Fisher score. The primary outcome was a 1-year modified Rankin Scale score ≤3. Secondary outcomes included time from diagnosis to securing aneurysm, 1-year mortality, and a cost analysis. Results: Among 128 consecutive aSAH transferred from Guadeloupe, 93 were matched with 93 patients from the Paris area. The proportion of patients with 1-year modified Rankin Scale ≤3 (75% vs 82%, respectively; P = 0.5) and 1-year mortality (18% vs 14%, respectively; P = 0.2) was similar in the Guadeloupe and Paris groups. The median (interquartile range: Q1, Q3) time from diagnosis to securing the aneurysm was higher in the patients from Guadeloupe than those from Paris (48 [30, 63] h vs 23 [12, 24] h, respectively; P < 0.001). Guadeloupean patients received mechanical ventilation (58% vs 38%; P < 0.001) and external ventricular drainage (55% vs 39%; P = 0.005) more often than those from Paris. The additional cost of treating a Guadeloupe patient in Paris was estimated at 7580 Euros or 17% of the estimated cost in Guadeloupe. Conclusions: Long-distance aeromedical evacuation of patients with aSAH from Guadeloupe to Paris resulted in a 25-hour increase in time to aneurysm coiling embolization time but did not impact 1-year functional outcomes or mortality.
- 24 July 2024
- Published by Wolters Kluwer Health in Journal of Neurosurgical Anesthesiology
- Vol. 37 (3) , 279-287
Open AccessOutcome of Aneurysmal Subarachnoid Hemorrhage Not Altered With Transatlantic Airplane Transfer: A Bicentric Matched Case-control Study
Objective: It is recommended that ruptured cerebral aneurysms are treated in a high-volume center within 72 hours of ictus. We assessed the impact of long-distance aeromedical evacuation in patients presenting aSAH. Methods: This case-control study compared patients with aneurysmal subarachnoid hemorrhage (aSAH) who had a 6750 km air transfer from Guadeloupe (a Caribbean island) to Paris, France, for neurointerventional management in a tertiary center with a matched cohort from Paris region treated in the same center over a 10-year period (2010 to 2019). The 2 populations were matched on age, sex, World Federation of Neurological Surgeons score, and Fisher score. The primary outcome was a 1-year modified Rankin Scale score ≤3. Secondary outcomes included time from diagnosis to securing aneurysm, 1-year mortality, and a cost analysis. Results: Among 128 consecutive aSAH transferred from Guadeloupe, 93 were matched with 93 patients from the Paris area. The proportion of patients with 1-year modified Rankin Scale ≤3 (75% vs 82%, respectively; P = 0.5) and 1-year mortality (18% vs 14%, respectively; P = 0.2) was similar in the Guadeloupe and Paris groups. The median (interquartile range: Q1, Q3) time from diagnosis to securing the aneurysm was higher in the patients from Guadeloupe than those from Paris (48 [30, 63] h vs 23 [12, 24] h, respectively; P < 0.001). Guadeloupean patients received mechanical ventilation (58% vs 38%; P < 0.001) and external ventricular drainage (55% vs 39%; P = 0.005) more often than those from Paris. The additional cost of treating a Guadeloupe patient in Paris was estimated at 7580 Euros or 17% of the estimated cost in Guadeloupe. Conclusions: Long-distance aeromedical evacuation of patients with aSAH from Guadeloupe to Paris resulted in a 25-hour increase in time to aneurysm coiling embolization time but did not impact 1-year functional outcomes or mortality.
- Open Access
- 12 April 2024
- Published by Springer Nature in BMC Anesthesiology
- Vol. 24 (1) , 1-13
One-year survival of aneurysmal subarachnoid hemorrhage after airplane transatlantic transfer – a monocenter retrospective study
Background: Aneurysmal subarachnoid hemorrhage (aSAH) is preferentially treated by prompt endovascular coiling, which is not available in Guadeloupe. Subsequently, patients are transferred to Paris, France mainland, by commercial airplane (6751 km flight) after being managed according to guidelines. This study describes the characteristics, management and outcomes related to these patients. Methods: Retrospective observational cohort study of 148 patients admitted in intensive care unit for a suspected aSAH and transferred by airplane over a 10-year period (2010–2019). Results: The median [interquartile range] age was 53 [45–64] years and 61% were female. On admission, Glasgow coma scale was 15 [13–15], World Federation of Neurological Surgeons (WFNS) grading scale was 1 [1–3] and Fisher scale was 4 [2–4]. External ventricular drainage and mechanical ventilation were performed prior to the flight respectively in 42% and 47% of patients. One-year mortality was 16% over the study period. By COX logistic regression analysis, acute hydrocephalus (hazard ratio [HR] 2.34, 95% confidence interval [CI] 0.98–5.58) prior to airplane transfer, WFNS grading scale on admission (HR 1.53, 95% CI 1.16–2.02) and age (OR 1.03, 95% 1.00–1.07) were associated with one-year mortality. Conclusion: When necessary, transatlantic air transfer of patients with suspected aSAH after management according to local guidelines seems feasible and safe.
- 12 April 2024
- Published by Springer Nature in BMC Anesthesiology
- Vol. 24 (1) , 1-13
Open AccessOne-year survival of aneurysmal subarachnoid hemorrhage after airplane transatlantic transfer – a monocenter retrospective study
Background: Aneurysmal subarachnoid hemorrhage (aSAH) is preferentially treated by prompt endovascular coiling, which is not available in Guadeloupe. Subsequently, patients are transferred to Paris, France mainland, by commercial airplane (6751 km flight) after being managed according to guidelines. This study describes the characteristics, management and outcomes related to these patients. Methods: Retrospective observational cohort study of 148 patients admitted in intensive care unit for a suspected aSAH and transferred by airplane over a 10-year period (2010–2019). Results: The median [interquartile range] age was 53 [45–64] years and 61% were female. On admission, Glasgow coma scale was 15 [13–15], World Federation of Neurological Surgeons (WFNS) grading scale was 1 [1–3] and Fisher scale was 4 [2–4]. External ventricular drainage and mechanical ventilation were performed prior to the flight respectively in 42% and 47% of patients. One-year mortality was 16% over the study period. By COX logistic regression analysis, acute hydrocephalus (hazard ratio [HR] 2.34, 95% confidence interval [CI] 0.98–5.58) prior to airplane transfer, WFNS grading scale on admission (HR 1.53, 95% CI 1.16–2.02) and age (OR 1.03, 95% 1.00–1.07) were associated with one-year mortality. Conclusion: When necessary, transatlantic air transfer of patients with suspected aSAH after management according to local guidelines seems feasible and safe.
- Open Access
Prognosis of aneurysmal subarachnoid hemorrhage not altered with transatlantic airplane transfer. A bicentric matched case–control study
Background The treatment of a ruptured aneurysm, in a center with expertise in aneurysmal subarachnoid hemorrhage (aSAH), is recommended preferably within 24 to 72 hr. We assessed the impact of long-distance aeromedical evacuation in patients presenting aSAH in a remote island without neuro-interventional capacities. Methods This was a case–control study of patients with aSAH flown from a French Caribbean island (Guadeloupe) to Paris, France (6750 km), for neuro-interventional and neuro-ICU management and identical patients from the Paris region over a 10-year period (2010 to 2019). The two populations were matched on age, sex, World Federation of Neurological Surgeons score, and Fisher score. The primary outcome was the 1-year modified Rankin Scale (mRS) score divided into two categories: good outcome (mRS 0 to 3) and poor outcome (mRS 4 to 6). A cost study was added. Results Among 128 consecutive aSAH transferred from Guadeloupe, 93 could be matched with 93 patients with aSAH from the Paris area. The median [Q1,Q3] time from diagnosis to securing the aneurysm was 48 hr [30,63] in the Guadeloupe group versus 23 [12,24] in the control group (pConclusions Long distance aeromedical evacuation of Guadeloupe patients with aSAH resulted in a 25-hr increase in median embolization time but had no effect on mortality or functional prognosis at 1 year.
Open AccessPrognosis of aneurysmal subarachnoid hemorrhage not altered with transatlantic airplane transfer. A bicentric matched case–control study
Background The treatment of a ruptured aneurysm, in a center with expertise in aneurysmal subarachnoid hemorrhage (aSAH), is recommended preferably within 24 to 72 hr. We assessed the impact of long-distance aeromedical evacuation in patients presenting aSAH in a remote island without neuro-interventional capacities. Methods This was a case–control study of patients with aSAH flown from a French Caribbean island (Guadeloupe) to Paris, France (6750 km), for neuro-interventional and neuro-ICU management and identical patients from the Paris region over a 10-year period (2010 to 2019). The two populations were matched on age, sex, World Federation of Neurological Surgeons score, and Fisher score. The primary outcome was the 1-year modified Rankin Scale (mRS) score divided into two categories: good outcome (mRS 0 to 3) and poor outcome (mRS 4 to 6). A cost study was added. Results Among 128 consecutive aSAH transferred from Guadeloupe, 93 could be matched with 93 patients with aSAH from the Paris area. The median [Q1,Q3] time from diagnosis to securing the aneurysm was 48 hr [30,63] in the Guadeloupe group versus 23 [12,24] in the control group (pConclusions Long distance aeromedical evacuation of Guadeloupe patients with aSAH resulted in a 25-hr increase in median embolization time but had no effect on mortality or functional prognosis at 1 year.
- Open Access
Pain Control for Sickle Cell Crisis, a Novel Approach? A Retrospective Study
Background and Objectives: Pain management poses a significant challenge for patients experiencing vaso-occlusive crisis (VOC) in sickle cell disease (SCD). While opioid therapy is highly effective, its efficacy can be impeded by undesirable side effects. Local regional anesthesia (LRA), involving the deposition of a perineural anesthetic, provides a nociceptive blockade, local vasodilation and reduces the inflammatory response. However, the effectiveness of this therapeutic approach for VOC in SCD patients has been rarely reported up to now. The objective of this study was to assess the effectiveness of a single-shot local regional anesthesia (LRA) in reducing pain and consequently enhancing the management of severe vaso-occlusive crisis (VOC) in adults with sickle cell disease (SCD) unresponsive to conventional analgesic therapy. Materials and Methods: We first collected consecutive episodes of VOC in critical care (ICU and emergency room) for six months in 2022 in a French University hospital with a large population of sickle cell patients in the West Indies population. We also performed a systematic review of the use of LRA in SCD. The primary outcome was defined using a numeric pain score (NPS) and/or percentage of change in opioid use. Results: We enrolled nine SCD adults (28 years old, 4 females) for ten episodes of VOC in whom LRA was used for pain management. Opioid reduction within the first 24 h post block was −75% (50 to 96%). Similarly, the NPS decreased from 9/10 pre-block to 0–1/10 post-block. Five studies, including one case series with three patients and four case reports, employed peripheral nerve blocks for regional anesthesia. In general, local regional anesthesia (LRA) exhibited a reduction in pain and symptoms, along with a decrease in opioid consumption post-procedure. Conclusions: LRA improves pain scores, reduces opioid consumption in SCD patients with refractory pain, and may mitigate opioid-related side effects while facilitating the transition to oral analgesics. Furthermore, LRA is a safe and effective procedure.
Open AccessPain Control for Sickle Cell Crisis, a Novel Approach? A Retrospective Study
Background and Objectives: Pain management poses a significant challenge for patients experiencing vaso-occlusive crisis (VOC) in sickle cell disease (SCD). While opioid therapy is highly effective, its efficacy can be impeded by undesirable side effects. Local regional anesthesia (LRA), involving the deposition of a perineural anesthetic, provides a nociceptive blockade, local vasodilation and reduces the inflammatory response. However, the effectiveness of this therapeutic approach for VOC in SCD patients has been rarely reported up to now. The objective of this study was to assess the effectiveness of a single-shot local regional anesthesia (LRA) in reducing pain and consequently enhancing the management of severe vaso-occlusive crisis (VOC) in adults with sickle cell disease (SCD) unresponsive to conventional analgesic therapy. Materials and Methods: We first collected consecutive episodes of VOC in critical care (ICU and emergency room) for six months in 2022 in a French University hospital with a large population of sickle cell patients in the West Indies population. We also performed a systematic review of the use of LRA in SCD. The primary outcome was defined using a numeric pain score (NPS) and/or percentage of change in opioid use. Results: We enrolled nine SCD adults (28 years old, 4 females) for ten episodes of VOC in whom LRA was used for pain management. Opioid reduction within the first 24 h post block was −75% (50 to 96%). Similarly, the NPS decreased from 9/10 pre-block to 0–1/10 post-block. Five studies, including one case series with three patients and four case reports, employed peripheral nerve blocks for regional anesthesia. In general, local regional anesthesia (LRA) exhibited a reduction in pain and symptoms, along with a decrease in opioid consumption post-procedure. Conclusions: LRA improves pain scores, reduces opioid consumption in SCD patients with refractory pain, and may mitigate opioid-related side effects while facilitating the transition to oral analgesics. Furthermore, LRA is a safe and effective procedure.
- Open Access
- 9 December 2022
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 6 (8) , e12811
Platelet caspase‐1 and Bruton tyrosine kinase activation in patients with COVID‐19 is associated with disease severity and reversed in vitro by ibrutinib
- 9 December 2022
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 6 (8) , e12811
Open AccessPlatelet caspase‐1 and Bruton tyrosine kinase activation in patients with COVID‐19 is associated with disease severity and reversed in vitro by ibrutinib
- 16 June 2022
- Published by Societe de Reanimation de Langue Francaise in Médecine Intensive Réanimation
- Vol. 31 (2) , 107-116
Indications et délai de l’intubation orotrachéale en réanimation : état des lieux
L’intubation oro-trachéale et la ventilation mécanique font partie de l’arsenal thérapeutique courant en médecine intensive et réanimation. Elles visent à suppléer une défaillance respiratoire et peuvent être associées à la prise en charge de défaillances neurologiques ou hémodynamiques. Néanmoins l’intubation et la ventilation mécanique sont associées à des effets indésirables potentiellement graves. Les indications ne sont pas toujours bien codifiées, la question du délai de l’intubation est rarement abordée dans les recommandations et les différences de pratiques entre les centres ou les praticiens prennent une place importante dans le processus de décision. Au-delà de l’indication, le choix du bon moment pour l’intubation doit prendre en compte rapport bénéfice risque de la ventilation invasive ainsi qu’un bénéfice potentiel à éviter une intubation inutile mais qui s’associe à un risque d’intubation trop tardive. Dans cette mise au point, nous proposons une revue des données de la littérature sur la place et le délai de l’intubation oro-trachéale dans la prise en charge des défaillances respiratoires, hémodynamiques et neurologiques les plus fréquemment rencontrées en médecine intensive et réanimation.
- 16 June 2022
- Published by Societe de Reanimation de Langue Francaise in Médecine Intensive Réanimation
- Vol. 31 (2) , 107-116
Indications et délai de l’intubation orotrachéale en réanimation : état des lieux
L’intubation oro-trachéale et la ventilation mécanique font partie de l’arsenal thérapeutique courant en médecine intensive et réanimation. Elles visent à suppléer une défaillance respiratoire et peuvent être associées à la prise en charge de défaillances neurologiques ou hémodynamiques. Néanmoins l’intubation et la ventilation mécanique sont associées à des effets indésirables potentiellement graves. Les indications ne sont pas toujours bien codifiées, la question du délai de l’intubation est rarement abordée dans les recommandations et les différences de pratiques entre les centres ou les praticiens prennent une place importante dans le processus de décision. Au-delà de l’indication, le choix du bon moment pour l’intubation doit prendre en compte rapport bénéfice risque de la ventilation invasive ainsi qu’un bénéfice potentiel à éviter une intubation inutile mais qui s’associe à un risque d’intubation trop tardive. Dans cette mise au point, nous proposons une revue des données de la littérature sur la place et le délai de l’intubation oro-trachéale dans la prise en charge des défaillances respiratoires, hémodynamiques et neurologiques les plus fréquemment rencontrées en médecine intensive et réanimation.
- Top Cited Papers
- 22 February 2022
- Published by Springer Nature in Intensive Care Medicine
- Vol. 48 (4) , 458-466
Factors associated with acute mesenteric ischemia among critically ill ventilated patients with shock: a post hoc analysis of the NUTRIREA2 trial
Purpose Acute mesenteric ischemia (AMI) is a rare, but life-threatening condition occurring among critically ill patients. Several factors have been associated with AMI, but the causal link is debated, most studies being retrospective. Among these factors, enteral nutrition (EN) could be associated with AMI, in particular among patients with shock. We aimed to study the factors independently associated with AMI in a post hoc analysis of the NUTRIREA-2 trial including 2410 critically ill ventilated patients with shock, randomly assigned to receive EN or parenteral nutrition (PN). Methods Post hoc analysis of the NUTRIREA-2 trial was conducted. Ventilated adults with shock were randomly assigned to receive EN or PN. AMI was assessed by computed tomography, endoscopy, or laparotomy. Factors associated with AMI were studied by univariate and multivariate analysis. Results 2410 patients from 44 French intensive care units (ICUs) were included in the study: 1202 patients in the enteral group and 1208 patients in the parenteral group. The median age was 67 [58–76] years, with 67% men, a SAPS II score of 59 [46–74], and a medical cause for ICU admission in 92.7%. AMI was diagnosed among 24 (1%) patients, mainly by computed tomography (79%) or endoscopy (38%). The mechanism of AMI was non-occlusive mesenteric ischemia (n = 12), occlusive (n = 4), and indeterminate (n = 8). The median duration between inclusion in the trial and AMI diagnosis was 4 [1–11] days. Patients with AMI were older, had a higher SAPS II score at ICU admission, had higher plasma lactate, creatinine, and ASAT concentrations and lower hemoglobin concentration, had more frequently EN, dobutamine, and CVVHDF at inclusion, developed more frequently bacteremia during ICU stay, and had higher 28-day and 90-day mortality rates compared with patients without AMI. By multivariate analysis, AMI was independently associated with EN, dobutamine use, SAPS II score ≥ 62 and hemoglobin concentration ≤ 10.9 g/dL. Conclusion Among critically ill ventilated patients with shock, EN, dobutamine use, SAPS II score ≥ 62 and hemoglobin ≤ 10.9 g/dL were independently associated with AMI. Among critically ill ventilated patients requiring vasopressors, EN should be delayed or introduced cautiously in case of low cardiac output requiring dobutamine and/or in case of multiple organ failure with high SAPS II score.
- 22 February 2022
- Published by Springer Nature in Intensive Care Medicine
- Vol. 48 (4) , 458-466
Top Cited PapersFactors associated with acute mesenteric ischemia among critically ill ventilated patients with shock: a post hoc analysis of the NUTRIREA2 trial
Purpose Acute mesenteric ischemia (AMI) is a rare, but life-threatening condition occurring among critically ill patients. Several factors have been associated with AMI, but the causal link is debated, most studies being retrospective. Among these factors, enteral nutrition (EN) could be associated with AMI, in particular among patients with shock. We aimed to study the factors independently associated with AMI in a post hoc analysis of the NUTRIREA-2 trial including 2410 critically ill ventilated patients with shock, randomly assigned to receive EN or parenteral nutrition (PN). Methods Post hoc analysis of the NUTRIREA-2 trial was conducted. Ventilated adults with shock were randomly assigned to receive EN or PN. AMI was assessed by computed tomography, endoscopy, or laparotomy. Factors associated with AMI were studied by univariate and multivariate analysis. Results 2410 patients from 44 French intensive care units (ICUs) were included in the study: 1202 patients in the enteral group and 1208 patients in the parenteral group. The median age was 67 [58–76] years, with 67% men, a SAPS II score of 59 [46–74], and a medical cause for ICU admission in 92.7%. AMI was diagnosed among 24 (1%) patients, mainly by computed tomography (79%) or endoscopy (38%). The mechanism of AMI was non-occlusive mesenteric ischemia (n = 12), occlusive (n = 4), and indeterminate (n = 8). The median duration between inclusion in the trial and AMI diagnosis was 4 [1–11] days. Patients with AMI were older, had a higher SAPS II score at ICU admission, had higher plasma lactate, creatinine, and ASAT concentrations and lower hemoglobin concentration, had more frequently EN, dobutamine, and CVVHDF at inclusion, developed more frequently bacteremia during ICU stay, and had higher 28-day and 90-day mortality rates compared with patients without AMI. By multivariate analysis, AMI was independently associated with EN, dobutamine use, SAPS II score ≥ 62 and hemoglobin concentration ≤ 10.9 g/dL. Conclusion Among critically ill ventilated patients with shock, EN, dobutamine use, SAPS II score ≥ 62 and hemoglobin ≤ 10.9 g/dL were independently associated with AMI. Among critically ill ventilated patients requiring vasopressors, EN should be delayed or introduced cautiously in case of low cardiac output requiring dobutamine and/or in case of multiple organ failure with high SAPS II score.
- Open Access
- 23 December 2014
- Published by Springer Nature in Trials
- Vol. 15 (1) , 1-13
Impact of early enteral versus parenteral nutrition on mortality in patients requiring mechanical ventilation and catecholamines: study protocol for a randomized controlled trial (NUTRIREA-2)
Nutritional support is crucial to the management of patients receiving invasive mechanical ventilation (IMV) and the most commonly prescribed treatment in intensive care units (ICUs). International guidelines consistently indicate that enteral nutrition (EN) should be preferred over parenteral nutrition (PN) whenever possible and started as early as possible. However, no adequately designed study has evaluated whether a specific nutritional modality is associated with decreased mortality. The primary goal of this trial is to assess the hypothesis that early first-line EN, as compared to early first-line PN, decreases day 28 all-cause mortality in patients receiving IMV and vasoactive drugs for shock. The NUTRIREA-2 study is a multicenter, open-label, parallel-group, randomized controlled trial comparing early PN versus early EN in critically ill patients requiring IMV for an expected duration of at least 48 hours, combined with vasoactive drugs, for shock. Patients will be allocated at random to first-line PN for at least 72 hours or to first-line EN. In both groups, nutritional support will be started within 24 hours after IMV initiation. Calorie targets will be 20 to 25 kcal/kg/day during the first week, then 25 to 30 kcal/kg/day thereafter. Patients receiving PN may be switched to EN after at least 72 hours in the event of shock resolution (no vasoactive drugs for 24 consecutive hours and arterial lactic acid level below 2 mmol/L). On day 7, all patients receiving PN and having no contraindications to EN will be switched to EN. In both groups, supplemental PN may be added to EN after day 7 in patients with persistent intolerance to EN and inadequate calorie intake. We plan to recruit 2,854 patients at 44 participating ICUs. The NUTRIREA-2 study is the first large randomized controlled trial designed to assess the hypothesis that early EN improves survival compared to early PN in ICU patients. Enrollment started on 22 March 2013 and is expected to end in November 2015. ClinicalTrials.gov Identifier: NCT01802099 (registered 27 February 2013)
- 23 December 2014
- Published by Springer Nature in Trials
- Vol. 15 (1) , 1-13
Open AccessImpact of early enteral versus parenteral nutrition on mortality in patients requiring mechanical ventilation and catecholamines: study protocol for a randomized controlled trial (NUTRIREA-2)
Nutritional support is crucial to the management of patients receiving invasive mechanical ventilation (IMV) and the most commonly prescribed treatment in intensive care units (ICUs). International guidelines consistently indicate that enteral nutrition (EN) should be preferred over parenteral nutrition (PN) whenever possible and started as early as possible. However, no adequately designed study has evaluated whether a specific nutritional modality is associated with decreased mortality. The primary goal of this trial is to assess the hypothesis that early first-line EN, as compared to early first-line PN, decreases day 28 all-cause mortality in patients receiving IMV and vasoactive drugs for shock. The NUTRIREA-2 study is a multicenter, open-label, parallel-group, randomized controlled trial comparing early PN versus early EN in critically ill patients requiring IMV for an expected duration of at least 48 hours, combined with vasoactive drugs, for shock. Patients will be allocated at random to first-line PN for at least 72 hours or to first-line EN. In both groups, nutritional support will be started within 24 hours after IMV initiation. Calorie targets will be 20 to 25 kcal/kg/day during the first week, then 25 to 30 kcal/kg/day thereafter. Patients receiving PN may be switched to EN after at least 72 hours in the event of shock resolution (no vasoactive drugs for 24 consecutive hours and arterial lactic acid level below 2 mmol/L). On day 7, all patients receiving PN and having no contraindications to EN will be switched to EN. In both groups, supplemental PN may be added to EN after day 7 in patients with persistent intolerance to EN and inadequate calorie intake. We plan to recruit 2,854 patients at 44 participating ICUs. The NUTRIREA-2 study is the first large randomized controlled trial designed to assess the hypothesis that early EN improves survival compared to early PN in ICU patients. Enrollment started on 22 March 2013 and is expected to end in November 2015. ClinicalTrials.gov Identifier: NCT01802099 (registered 27 February 2013)